Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma.

Fiche publication

Date publication

août 2024

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LEROUX Agnès

Tous les auteurs :
Dufresne A, Pokras S, Meurgey A, Chabaud S, Toulmonde M, Bompas E, Le Cesne A, Robin YM, Duffaud F, Valentin T, El Zein S, Leroux A, Dubray-Longeras P, Firmin N, de Pinieux G, Noal S, Delfour C, Bollard J, Tonon L, Biette A, Gadot N, Attignon V, Jean-Denis M, Woessner M, Klohe E, Thayaparan T, Eleftheriadou I, Blouch K, Nathenson MJ, Blay JY

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39153316

Résumé

To better understand the importance of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and human leukocyte antigen (HLA) subtype in treatment decision making, further investigation of their prevalence and prognostic impact among patients with metastatic synovial sarcoma (mSS) is needed.